Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
Ravindra Uppaluri(Brigham and Women's Hospital), Douglas Adkins(Washington University in St. Louis), Anupama Hooda-Nehra(Rutgers, The State University of New Jersey), Makoto Tahara(National Cancer Center Hospital East), Kimberly Benjamin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Rebecca D. Chernock(Washington University in St. Louis), Nicolas Mach(University of Geneva), William H. Westra(Mount Sinai Hospital), Aron Popovtzer(Hebrew University of Jerusalem), Gustavo Vasconcelos Alves(Marqués de Valdecilla University Hospital), R. Bryan Bell(Providence Portland Medical Center), Tomasz A. Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Nobuhiko Oridate(Yokohama City University), Iane Pinto Figueiredo Lima, Brett Hughes(Royal Brisbane and Women's Hospital), Nancy Y. Lee(Memorial Sloan Kettering Cancer Center), Marc Oliva(Princess Margaret Cancer Centre), Burak Gümüşçü(Merck & Co., Inc., Rahway, NJ, USA (United States)), Simon Laban(University Hospital Ulm), Christophe Le Tourneau(Institut Curie), Diogo Alpuim Costa(Hospital do Desterro), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Irene Braña(Vall d'Hebron Institute of Oncology), Robert I. Haddad(Georgetown University), Tsutomu Ueda(Hiroshima University), Ursula C. Schroeder(University of Lübeck), Cristina P. Rodriguez(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Yungan Tao(Université Paris-Saclay), Paul‐Stefan Mauz(University Children's Hospital Tübingen), Yevhen Korobko(National Cancer Institute), Thorsten Fuereder(Medical University of Vienna), Cole Manschot(Merck & Co., Inc., Rahway, NJ, USA (United States)), A L Klochikhin
Cited by 277
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2004|3.2k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k